Anavex Life Sciences Corp.

NasdaqGS:AVXL Stok Raporu

Piyasa değeri: US$660.6m

Anavex Life Sciences Gelecekteki Büyüme

Future kriter kontrolleri 3/6

Anavex Life Sciences kazanç ve gelirinin sırasıyla yıllık 47.7% ve 52.4% oranında artması tahmin edilirken, EPS'nin yıllık 52.3% oranında büyümesi bekleniyor.

Anahtar bilgiler

47.7%

Kazanç büyüme oranı

52.3%

EPS büyüme oranı

Biotechs kazanç büyümesi28.0%
Gelir büyüme oranı52.4%
Gelecekteki özkaynak getirisin/a
Analist kapsamı

Low

Son güncelleme04 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Anavex: Understanding Their Latest Alzheimer's Data News With Caution

Nov 05

Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)

Oct 08

Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising

Jul 29

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Jul 17
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Apr 01
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

Sep 19
Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation

We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

May 10
We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow

Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

Jan 16
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Oct 01
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia

Sep 19

Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease

Sep 07

Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01

Aug 09

We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Jun 17
We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth

Anavex: Increasing Shareholder Value Against All Odds

May 31

Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease

Mar 23

We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Mar 03
We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn

Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease

Feb 09

Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity

Feb 02

Anavex: 2022 Has Major, Pivotal Catalysts

Jan 17

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Nov 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?

Nov 05

Anavex Life Sciences: Still Room To Run

Aug 29

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Jul 30
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Anavex: A Catalyst-Rich Year

Jul 05

Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers

Jun 21

Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease

Jun 14

Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment

Jun 08

Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease

Apr 28

Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Apr 16
Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:AVXL - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
TarihGelirKazançlarSerbest Nakit AkışıFaaliyetlerden NakitAvg. Analist Sayısı
9/30/20276304028226102
9/30/20263904815427382
9/30/2025N/A80-602223
9/30/2024N/A-46-58-393
6/30/2024N/A-42-30-30N/A
3/31/2024N/A-41-32-32N/A
12/31/2023N/A-43-29-29N/A
9/30/2023N/A-48-28-28N/A
6/30/2023N/A-52-26-26N/A
3/31/2023N/A-53-25-25N/A
12/31/2022N/A-50-27-27N/A
9/30/2022N/A-48-24-24N/A
6/30/2022N/A-45-28-28N/A
3/31/2022N/A-43-28-28N/A
12/31/2021N/A-41-26-26N/A
9/30/2021N/A-38-30-30N/A
6/30/2021N/A-32-29-29N/A
3/31/2021N/A-28-25-25N/A
12/31/2020N/A-28-23-23N/A
9/30/2020N/A-26-21-21N/A
6/30/2020N/A-26-18-18N/A
3/31/2020N/A-26-21-21N/A
12/31/2019N/A-26-20-20N/A
9/30/2019N/A-26-19-19N/A
6/30/2019N/A-26-20-20N/A
3/31/2019N/A-23-15-15N/A
12/31/2018N/A-20-13-13N/A
9/30/2018N/A-17-13-13N/A
6/30/2018N/A-17-11-11N/A
3/31/2018N/A-18N/A-12N/A
12/31/2017N/A-14N/A-9N/A
9/30/2017N/A-13N/A-9N/A
6/30/2017N/A-15N/A-9N/A
3/31/2017N/A-13N/A-8N/A
12/31/2016N/A-14N/A-9N/A
9/30/2016N/A-15N/A-9N/A
6/30/2016N/A-14N/A-9N/A
3/31/2016N/A-16N/A-8N/A
12/31/2015N/A-15N/A-7N/A
9/30/2015N/A-12N/A-4N/A
6/30/2015N/A-15N/A-4N/A
3/31/2015N/A-12N/A-3N/A
12/31/2014N/A-11N/A-3N/A
9/30/2014N/A-10N/A-3N/A
6/30/2014N/A-5N/A-2N/A
3/31/2014N/A-4N/A-1N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AVXL önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: AVXL önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: AVXL önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: AVXL gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: AVXL gelecek yıl gelir elde edemeyeceği tahmin ediliyor.


Hisse Başına Kazanç Büyüme Tahminleri


Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AVXL 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok


Büyüyen şirketleri keşfedin